Anzeige
Mehr »
Login
Samstag, 20.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AC4K | ISIN: US28106W1036 | Ticker-Symbol: 8EM
Tradegate
19.04.24
20:48 Uhr
4,992 Euro
-0,236
-4,51 %
1-Jahres-Chart
EDITAS MEDICINE INC Chart 1 Jahr
5-Tage-Chart
EDITAS MEDICINE INC 5-Tage-Chart
RealtimeGeldBriefZeit
5,0805,24019.04.
5,1385,19619.04.

Aktuelle News zur EDITAS MEDICINE Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
07.03.1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right.40
29.02.The Latest Analyst Ratings For Editas Medicine23
29.02.Editas Medicine, Inc. (EDIT) Q4 2023 Earnings Call Transcript10
29.02.Editas (EDIT) Q4 Earnings & Revenues Top Estimates, Stock Up8
28.02.Editas Medicine, Inc. - S-8, Securities to be offered to employees in employee benefit plans1
28.02.Editas Medicine, Inc. - 10-K, Annual Report5
28.02.Editas Medicine rises on narrower Q4 loss10
28.02.Editas spikes as Vertex Pharma deal boosts Q4 topline56
28.02.Editas Medicine, Inc. - 8-K, Current Report5
28.02.Editas Medicine GAAP EPS of -$0.23 beats by $0.23, revenue of $60.04M beats by $52.32M10
28.02.Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates830Company aligned with FDA that RUBY is a single Phase 1/2/3 trial On track to present additional clinical data from the RUBY trial and the EdiTHAL trial of reni-cel in mid-2024 and additional updates...
► Artikel lesen
27.02.Earnings Outlook For Editas Medicine16
27.02.Editas Medicine Q4 2023 Earnings Preview6
21.02.Editas Medicine, Inc.: Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events8
15.01.Down 88%, Could Editas Medicine Be a Good Investment Now?24
08.01.Editas Medicine, Inc.: Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference7
08.01.Better Gene-Editing Stock: Editas Medicine vs. Intellia Therapeutics41
02.01.Editas (EDIT) Stock Gains 23% in the Past 6 Months: Here's Why5
23.12.23Editas Just Caught a Break Thanks to Vertex Pharmaceuticals28
14.12.23Vertex licenses Editas' gene editing technology in $100m deal23
Seite:  Weiter >>
51 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1